Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...

Big Brother UK star Aisleyne Horgan-Wallace said she “thought she was going to die” after taking fake Ozempic. Horgan-Wallace ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

These stocks have climbed more than 80% and 200% over the past three years. But demand for their products and potential ...